Wei Y - Search Results

1

KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target.

Wei Y, Ren X, Galbo PM Jr, Moerdler S, Wang H, Sica RA, Etemad-Gilbertson B, Shi L, Zhu L, Tang X, Lin Q, Peng M, Guan F, Zheng D, Chinai JM, Zang X. Wei Y, et al. Sci Immunol. 2021 Jul 9;6(61):eabf9792. doi: 10.1126/sciimmunol.abf9792. Sci Immunol. 2021. PMID: 34244312 Free PMC article.

2

The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial.

John P, Wei Y, Liu W, Du M, Guan F, Zang X. John P, et al. Among authors: wei y. Trends Pharmacol Sci. 2019 Nov;40(11):883-896. doi: 10.1016/j.tips.2019.09.008. Epub 2019 Oct 31. Trends Pharmacol Sci. 2019. PMID: 31677920 Free PMC article. Review.

3

The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy.

John P, Pulanco MC, Galbo PM Jr, Wei Y, Ohaegbulam KC, Zheng D, Zang X. John P, et al. Among authors: wei y. Nat Commun. 2022 May 6;13(1):2506. doi: 10.1038/s41467-022-30143-8. Nat Commun. 2022. PMID: 35523809 Free PMC article.

4

Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell-mediated antitumor immunity.

Ren X, Peng M, Xing P, Wei Y, Galbo PM Jr, Corrigan D, Wang H, Su Y, Dong X, Sun Q, Li Y, Zhang X, Edelmann W, Zheng D, Zang X. Ren X, et al. Among authors: wei y. J Clin Invest. 2022 Nov 15;132(22):e163620. doi: 10.1172/JCI163620. J Clin Invest. 2022. PMID: 36377656 Free PMC article.

5

A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression.

Liu Y, John P, Nishitani K, Cui J, Nishimura CD, Christin JR, Couturier N, Ren X, Wei Y, Pulanco MC, Galbo PM Jr, Zhang X, Fu W, Cui W, Bartholdy BA, Zheng D, Lauvau G, Fineberg SA, Oktay MH, Zang X, Guo W. Liu Y, et al. Among authors: wei y. Dev Cell. 2023 Dec 4;58(23):2700-2717.e12. doi: 10.1016/j.devcel.2023.10.010. Epub 2023 Nov 13. Dev Cell. 2023. PMID: 37963469

6

Functional Contribution and Clinical Implication of Cancer-Associated Fibroblasts in Glioblastoma.

Galbo PM Jr, Madsen AT, Liu Y, Peng M, Wei Y, Ciesielski MJ, Fenstermaker RA, Graff S, Montagna C, Segall JE, Sidoli S, Zang X, Zheng D. Galbo PM Jr, et al. Among authors: wei y. Clin Cancer Res. 2024 Feb 16;30(4):865-876. doi: 10.1158/1078-0432.CCR-23-0493. Clin Cancer Res. 2024. PMID: 38060213

7

TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors.

Nishimura CD, Corrigan D, Zheng XY, Galbo PM Jr, Wang S, Liu Y, Wei Y, Suo L, Cui W, Mercado N, Zheng D, Zhang CC, Zang X. Nishimura CD, et al. Among authors: wei y. Sci Adv. 2024 May 10;10(19):eadk1857. doi: 10.1126/sciadv.adk1857. Epub 2024 May 8. Sci Adv. 2024. PMID: 38718110 Free PMC article.

8

FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.

Li P, Huang T, Zou Q, Liu D, Wang Y, Tan X, Wei Y, Qiu H. Li P, et al. Among authors: wei y. J Immunol. 2019 May 15;202(10):3065-3075. doi: 10.4049/jimmunol.1801199. Epub 2019 Apr 12. J Immunol. 2019. PMID: 30979816

9

CALCOCO2/NDP52 associates with RAB9 to initiate an antiviral response to hepatitis B virus infection through a lysosomal degradation pathway.

Cui S, Faure M, Wei Y. Cui S, et al. Among authors: wei y. Autophagy. 2024 May 16:1-3. doi: 10.1080/15548627.2024.2353499. Online ahead of print. Autophagy. 2024. PMID: 38752371

10

Palladium catalyzed stereoselective intramolecular [3 + 2] cycloaddition reactions of (E) & (Z)-ene-vinylidenecyclopropanes.

Ning C, Yu ZQ, Wei Y, Shi M. Ning C, et al. Among authors: wei y. Org Biomol Chem. 2024 May 16. doi: 10.1039/d4ob00607k. Online ahead of print. Org Biomol Chem. 2024. PMID: 38752342

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22,634 results

Search Page